Therapeutic challenges in hepatitis C-infected injection drug using patients 英文参考文献.docVIP

Harm Reduction Journal BioMedCentral Review Open Access Therapeutic challenges in hepatitis C-infected injection drug using patients Curtis L Cooper*1,2 and Edward J Mills2,3 Address: 1Associate Professor of Medicine-University of Ottawa Hospital, Division of Infectious Diseases-The Ottawa Hospital, Ottawa, Canada, 2Centre for International Health and Human Rights Studies, Toronto, Canada and 3Faculty of Health Sciences, Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada Email: Curtis L Cooper* - ccooper@ottawahospital.on.ca; Edward J Mills - EMILLS@ * Corresponding author Published: 10 November 2006 Received: 05 August 2006 Accepted: 10 November 2006 Harm Reduction Journal 2006, 3:31 doi:10.1186/1477-7517-3-31 This article is available from: /content/3/1/31 ? 2006 Cooper and Mills; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Hepatitis C Viral (HCV) infection in the injection drug user (IDU) population is a major medical concern. Concurrent substance abuse, co-morbid mental health conditions, poor socioeconomic status and a complex treatment protocol that is often incompatible with the life styles of IDUs combine to account for poor uptake and completion of HCV treatment. This article discusses HCV antiviral treatment issues relevant to IDUs chronically infected with this virus. The effect of non-injected substances of abuse on treatment outcome is considered. Priority issues requiring research are discussed. Background Influence of substance use on natural history of HCV Not all individuals with chronic HCV infection will progress to advanced stages of fibrosis and end-stage liver disease. During the initial period of evaluation of a HCV infected patie